Description

Cantuzumab mertansine (SB-408075; huC242-DM1), an ADC, is an immunoconjugate of the potent maytansine derivative (DM1; HY-19792) and the humanized monoclonal antibody (huC242) directed to CanAg. Cantuzumab mertansine has cytotoxic toward colon cancer cells and has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts[1][2].–Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Paul R Helft, et al. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 1;10(13):4363-8.|[2]Anthony W. Tolcher, et al. Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study. J Clin Oncol. 2003 Jan 15;21(2):211-22.-CASNumber-400010-39-1-MolecularWeight-150000 (average)-Compound Purity–SMILES-[Cantuzumab mertansine]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Microtubule/Tubulin-Isoform–Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton-MCE Product type-ADC Related